ONO-AE3-208

ONO-AE3-208 is a selective, orally active small molecule antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 (PTGER4). Developed by Ono Pharmaceutical, ONO-AE3-208 binds to the orthosteric site of the EP4 receptor with high affinity (Ki of 1.3 nM), blocking PGE2-mediated signaling. It exhibits significantly lower potency for other prostanoid receptors, such as EP3, FP, and TP, and shows no affinity for EP1, EP2, DP, or IP receptors. In preclinical research, ONO-AE3-208 has been widely investigated for its potential to suppress tumor progression, cell migration, invasion, and metastasis in various cancers, including breast and prostate cancers. It has also been studied in animal models of inflammatory diseases, such as experimental autoimmune encephalomyelitis (EAE), abdominal aortic aneurysm, and colitis. ONO-AE3-208 is primarily utilized as a research-use-only laboratory tool.

Other names

4-Cyano-2-[[2-(4-fluoro-1-naphthalenyl)-1-oxopropyl]amino]benzenebutanoic acid4-[4-cyano-2-[2-(4-fluoronaphthalen-1-yl)propanoylamino]phenyl]butanoic acid